<?xml version="1.0" encoding="UTF-8"?>
<p>Due to a gap in research on the treatment of MERS in pregnancy, there are no therapeutic options currently recommended for pregnant women [
 <xref rid="B58-viruses-12-00194" ref-type="bibr">58</xref>]. Therapies under development and testing may be considered inappropriate for pregnant women due to the unknown potential for teratogenic effects. For example, during the 2003 SARS outbreak, ribavirin was administered to pregnant women with severe cases of the disease, but ribavirin therapy has been documented to increase the risk of teratogenic effects in newborns [
 <xref rid="B58-viruses-12-00194" ref-type="bibr">58</xref>]. 
</p>
